Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Bolt Biotherapeutics price target lowered to $13 from $16 at Stifel » 14:34
05/13/22
05/13
14:34
05/13/22
14:34
BOLT

Bolt Biotherapeutics

$1.51 /

-0.04 (-2.58%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey lowered the firm's price target on Bolt Biotherapeutics to $13 from $16 and keeps a Buy rating on the shares following the company's Q1 earnings report and corporate update. He believes investor perception of the longer-term opportunity for BDC-1001 will likely "remain appropriately muted" based on competitive dynamics in the treatment of HER2+ solid tumors and his reduced price target mostly reflects revised financing assumptions, Willey said.

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$1.51 /

-0.04 (-2.58%)

BOLT Bolt Biotherapeutics
$1.51 /

-0.04 (-2.58%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
BOLT Bolt Biotherapeutics
$1.51 /

-0.04 (-2.58%)

BOLT Bolt Biotherapeutics
$1.51 /

-0.04 (-2.58%)

Earnings
Bolt Biotherapeutics reports Q1 EPS (64c), consensus (72c) » 16:31
05/12/22
05/12
16:31
05/12/22
16:31
BOLT

Bolt Biotherapeutics

$1.55 /

+0.075 (+5.08%)

Reports Q1 revenue $813K,…

Reports Q1 revenue $813K, consensus $370K. "Our lead program, BDC-1001, for patients with HER2-expressing solid tumors is on track and we expect to complete both our monotherapy and combination dose escalation arms and select a recommended Phase 2 dose in the second half of 2022," said Randall C. Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "We continue to apply our expertise in myeloid biology to advance our diversified pipeline of novel Boltbody ISACs and our first-in-class Dectin-2 agonist antibody program. Our strong cash position and multiple collaborations with leading therapeutic antibody companies are expected to provide us with the funding to achieve key clinical milestones with our most promising candidates in a cash-efficient manner."

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$1.55 /

+0.075 (+5.08%)

BOLT Bolt Biotherapeutics
$1.55 /

+0.075 (+5.08%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
BOLT Bolt Biotherapeutics
$1.55 /

+0.075 (+5.08%)

BOLT Bolt Biotherapeutics
$1.55 /

+0.075 (+5.08%)

Over a month ago
On The Fly
What You Missed On Wall Street This Morning » 12:14
03/31/22
03/31
12:14
03/31/22
12:14
WBA

Walgreens Boots Alliance

$45.10 /

-2.34 (-4.93%)

, AMZN

Amazon.com

$3,304.86 /

-18.19 (-0.55%)

, JPM

JPMorgan

$138.58 /

-1.91 (-1.36%)

, TPX

Tempur Sealy

$28.05 /

-0.95 (-3.28%)

, PATH

UiPath

$21.66 /

-7.38 (-25.41%)

, EXFY

Expensify

$16.27 /

-2.365 (-12.69%)

, AMD

AMD

$111.17 /

-8.03 (-6.74%)

, HPQ

HP Inc.

$36.74 /

-2.095 (-5.39%)

, DELL

Dell Technologies

$51.42 /

-2.86 (-5.27%)

, FIVE

Five Below

$162.17 /

+1.65 (+1.03%)

, COIN

Coinbase

$193.50 /

-3.2 (-1.63%)

, SNOW

Snowflake

$235.25 /

+3.6 (+1.55%)

, VIPS

Vipshop

$9.26 /

+0.05 (+0.54%)

, FLEX

Flex

$18.96 /

+1.595 (+9.19%)

, AMLX

Amylyx

$13.40 /

-1.55 (-10.37%)

, IQ

iQIYI

$4.64 /

-0.405 (-8.03%)

, BIDU

Baidu

$134.85 /

-9.02 (-6.27%)

, SHCR

Sharecare

$2.73 /

-0.55 (-16.79%)

, NNDM

Nano Dimension

$3.57 /

-0.26 (-6.80%)

, AAPL

Apple

$177.06 /

-0.615 (-0.35%)

, QCOM

Qualcomm

$154.02 /

+1.295 (+0.85%)

, FB

Meta Platforms

$224.95 /

-2.82 (-1.24%)

, F

Ford

$17.13 /

-0.15 (-0.87%)

, TSLA

Tesla

$1,097.57 /

+3.66 (+0.33%)

, MASI

Masimo

$148.79 /

-6.28 (-4.05%)

, VRRM

Verra Mobility

$16.57 /

+0.89 (+5.68%)

, NNOX

Nano-X Imaging

$10.98 /

+1.55 (+16.44%)

, DARE

Dare Bioscience

$1.55 /

+0.09 (+6.16%)

, BOLT

Bolt Biotherapeutics

$2.72 /

-0.06 (-2.16%)

Get caught up quickly on…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

VRRM Verra Mobility
$16.57 /

+0.89 (+5.68%)

VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

TSLA Tesla
$1,097.57 /

+3.66 (+0.33%)

TPX Tempur Sealy
$28.05 /

-0.95 (-3.28%)

SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

SHCR Sharecare
$2.73 /

-0.55 (-16.79%)

QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

PATH UiPath
$21.66 /

-7.38 (-25.41%)

NNOX Nano-X Imaging
$10.98 /

+1.55 (+16.44%)

NNDM Nano Dimension
$3.57 /

-0.26 (-6.80%)

MASI Masimo
$148.79 /

-6.28 (-4.05%)

JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

IQ iQIYI
$4.64 /

-0.405 (-8.03%)

HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

FLEX Flex
$18.96 /

+1.595 (+9.19%)

FIVE Five Below
$162.17 /

+1.65 (+1.03%)

FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

F Ford
$17.13 /

-0.15 (-0.87%)

DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

DARE Dare Bioscience
$1.55 /

+0.09 (+6.16%)

COIN Coinbase
$193.50 /

-3.2 (-1.63%)

BOLT Bolt Biotherapeutics
$2.72 /

-0.06 (-2.16%)

BIDU Baidu
$134.85 /

-9.02 (-6.27%)

AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

AMLX Amylyx
$13.40 /

-1.55 (-10.37%)

AMD AMD
$111.17 /

-8.03 (-6.74%)

AAPL Apple
$177.06 /

-0.615 (-0.35%)

WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

01/10/22 Mizuho
Walgreens Boots Alliance price target raised to $56 from $51 at Mizuho
12/22/21 UBS
Walgreens Boots Alliance price target raised to $52 from $50 at UBS
12/22/21 Baird
Walgreens Boots Alliance price target raised to $70 from $68 at Baird
12/17/21 Morgan Stanley
Walgreens Boots Alliance downgraded to Underweight at Morgan Stanley
AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

03/29/22 Exane BNP Paribas
Amazon.com initiated with an Underperform at Exane BNP Paribas
03/28/22 Wedbush
Apple makes history, wins Oscar for Best Picture with CODA, says Wedbush
03/25/22 Evercore ISI
Evercore highlights 'four underappreciated elements' of Amazon story
03/22/22 Argus
eBay price target lowered to $69 from $88 at Argus
JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

03/28/22 Morgan Stanley
JPMorgan price target lowered to $161 from $170 at Morgan Stanley
02/14/22 Jefferies
JPMorgan cut to Hold at Jefferies amid bank rating adjustments
02/14/22 Jefferies
JPMorgan downgraded to Hold from Buy at Jefferies
01/18/22 UBS
JPMorgan price target lowered to $197 from $210 at UBS
TPX Tempur Sealy
$28.05 /

-0.95 (-3.28%)

03/30/22 Truist
Tempur Sealy price target lowered to $37 from $45 at Truist
02/23/22 Loop Capital
Tempur Sealy price target lowered to $35 from $40 at Loop Capital
02/23/22 KeyBanc
Tempur Sealy price target lowered to $46 from $55 at KeyBanc
02/23/22 Wedbush
Tempur Sealy price target lowered to $40 from $55 at Wedbush
PATH UiPath
$21.66 /

-7.38 (-25.41%)

03/31/22 RBC Capital
UiPath price target lowered to $32 from $37 at RBC Capital
03/31/22 BMO Capital
UiPath price target lowered to $29 from $52 at BMO Capital
03/31/22 Truist
UiPath price target lowered to $55 from $75 at Truist
03/31/22 Needham
UiPath price target lowered to $40 from $85 at Needham
EXFY Expensify
$16.27 /

-2.365 (-12.69%)

03/31/22 Loop Capital
Expensify price target lowered to $17 from $22 at Loop Capital
03/31/22 JMP Securities
Expensify price target lowered to $26 from $44 at JMP Securities
03/31/22 Citi
Expensify price target lowered to $27 from $35 at Citi
03/31/22 Piper Sandler
Expensify price target lowered to $25 from $45 at Piper Sandler
AMD AMD
$111.17 /

-8.03 (-6.74%)

03/31/22 Barclays
AMD downgraded to Equal Weight from Overweight at Barclays
03/27/22 Goldman Sachs
AMD downgraded to Buy from Conviction Buy at Goldman Sachs
03/25/22 BofA
BofA tactically most constructive on 'MANGO' stocks in U.S. Semiconductors
02/22/22 Bernstein
Bernstein upgrades AMD to Outperform with $150 price target
HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

03/31/22 Barclays
HP Inc. price target lowered to $29 from $30 at Barclays
03/31/22 Morgan Stanley
HP Inc. downgraded to Underweight from Equal Weight at Morgan Stanley
03/29/22 Morgan Stanley
HP rationale for Poly deal 'appears compelling,' says Morgan Stanley
03/29/22 Deutsche Bank
HP acquisition 'not cheap' for business struggling to grow, says Deutsche Bank
DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

03/31/22 Barclays
Dell Technologies price target lowered to $53 from $54 at Barclays
03/31/22 Morgan Stanley
Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/22 Evercore ISI
Dell Technologies upgraded to Outperform from In Line at Evercore ISI
02/25/22 Morgan Stanley
Dell Technologies price target lowered to $66 from $68 at Morgan Stanley
FIVE Five Below
$162.17 /

+1.65 (+1.03%)

03/31/22 Craig-Hallum
Five Below price target lowered to $230 from $240 at Craig-Hallum
03/31/22 Truist
Five Below price target lowered to $205 from $214 at Truist
03/31/22 Deutsche Bank
Five Below price target raised to $284 from $276 at Deutsche Bank
03/31/22 Loop Capital
Five Below price target lowered to $165 from $210 at Loop Capital
COIN Coinbase
$193.50 /

-3.2 (-1.63%)

03/30/22 US Tiger
Coinbase initiated with a Sell at US Tiger
03/22/22 Citi
Coinbase price target lowered to $275 from $300 at Citi
02/28/22 Compass Point
Coinbase price target lowered to $200 from $325 at Compass Point
02/25/22 Needham
Coinbase price target lowered to $360 from $420 at Needham
SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

03/31/22 Atlantic Equities
Atlantic starts 'priced for perfection' Snowflake with Neutral
03/31/22 Atlantic Equities
Snowflake initiated with a Neutral at Atlantic Equities
03/29/22 Exane BNP Paribas
Snowflake downgraded to Underperform from Neutral at Exane BNP Paribas
03/24/22 Truist
Snowflake price target lowered to $350 from $400 at Truist
VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

03/14/22 JPMorgan
Vipshop price target lowered to $7 from $9 at JPMorgan
03/07/22 Morgan Stanley
JD.com price target lowered to $85 from $98 at Morgan Stanley
02/24/22 Morgan Stanley
Vipshop downgraded to Equal Weight from Overweight at Morgan Stanley
01/03/22 CLSA
Vipshop price target lowered to $10 from $11.80 at CLSA
FLEX Flex
$18.96 /

+1.595 (+9.19%)

01/27/22 Craig-Hallum
Flex price target lowered to $25 from $31 at Craig-Hallum
05/25/21 Stifel
Plexus warning may be signal that supply constraints will worsen, says Stifel
05/07/21 Citi
Flex price target raised to $25 from $22 at Citi
05/06/21 Cross Research
Cross Research upgrades Flex to Buy after 'strong' Q4
AMLX Amylyx
$13.40 /

-1.55 (-10.37%)

03/31/22 H.C. Wainwright
Amylyx approval odds unchanged with panel vote, says H.C. Wainwright
03/29/22 H.C. Wainwright
Patient advocacy, data favor Amylyx into panel vote, says H.C. Wainwright
03/28/22 Jefferies
Reata drop on Amylyx docs an opportunity to accumulate shares, says Jefferies
03/28/22 Citi
Reata selloff following Amylyx briefing docs 'overdone,' says Citi
IQ iQIYI
$4.64 /

-0.405 (-8.03%)

03/14/22 JPMorgan
iQIYI downgraded to Underweight from Overweight at JPMorgan
03/02/22 JPMorgan
iQIYI upgraded to Overweight from Neutral at JPMorgan
01/14/22 HSBC
iQIYI price target lowered to $4.80 from $8.10 at HSBC
01/10/22 OTR Global
iQIYI ad business view downgraded to Negative from Mixed at OTR Global
BIDU Baidu
$134.85 /

-9.02 (-6.27%)

03/14/22 JPMorgan
Baidu double downgraded to Underweight at JPMorgan amid sector-wide selloff
03/14/22 JPMorgan
Baidu downgraded to Underweight from Overweight at JPMorgan
03/03/22 Susquehanna
Baidu price target raised to $200 from $175 at Susquehanna
03/02/22 China Renaissance
Baidu price target raised to $228 from $215 at China Renaissance
SHCR Sharecare
$2.73 /

-0.55 (-16.79%)

02/11/22 Goldman Sachs
Sharecare initiated with a Neutral at Goldman Sachs
01/18/22 BTIG
BTIG would expect Sharecare to raise 2022 guidance along with Q4 report
01/04/22 BTIG
Sharecare's announcements today 'significant positives,' says BTIG
11/24/21 BTIG
Sharecare 'offers excelling buying opportunity', says BTIG
NNDM Nano Dimension
$3.57 /

-0.26 (-6.80%)

AAPL Apple
$177.06 /

-0.615 (-0.35%)

03/31/22 BTIG
CoreCard weakness on report of Apple processing plans looks overdone, says BTIG
03/30/22 BofA
Apple's lower trade-in prices imply strong demand, says BofA
03/28/22 Morgan Stanley
Apple subscription offering can increase spend per user, says Morgan Stanley
QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

03/18/22 Piper Sandler
Piper 'pounding the table' on 'mis-valued' Qualcomm
02/04/22 Baird
Qualcomm price target raised to $250 from $200 at Baird
02/03/22 Bernstein
Qualcomm price target raised to $250 from $225 at Bernstein
02/03/22 Cowen
Qualcomm price target raised to $220 from $210 at Cowen
FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

03/28/22 Morgan Stanley
Pinterest cut to Equal Weight at Morgan Stanley amid challenging user trends
03/25/22 UBS
Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
03/17/22 Barclays
Barclays says Meta opening up feed positive for DoubleVerify, Integral Ad
03/15/22 Cleveland Research
Snap Q1 estimates raised at Cleveland Research
F Ford
$17.13 /

-0.15 (-0.87%)

03/28/22 Citi
Ford price target lowered to $18 from $23 at Citi
03/23/22 RBC Capital
RBC cut 2022, 2023 auto forecast on lingering supply chain issues
03/21/22 Morgan Stanley
Morgan Stanley sees Ford's FY26 BEV volume 1.5M units below company view
03/15/22 Jefferies
Ford price target lowered to $18 from $20 at Jefferies
TSLA Tesla
$1,097.57 /

+3.66 (+0.33%)

03/31/22 Morgan Stanley
Tesla emerging as energy on-shore infrastructure company, says Morgan Stanley
03/30/22 Morgan Stanley
Market saying Tesla 'far ahead' on securing EV supplies, says Morgan Stanley
03/30/22 Bernstein
Innovation can allow Tesla to take price but only for so long, says Bernstein
03/29/22 Credit Suisse
Credit Suisse expects Tesla Q1 deliveries of 307,000
MASI Masimo
$148.79 /

-6.28 (-4.05%)

03/31/22 Stifel
Masimo price target lowered to $175 from $250 at Stifel
03/31/22 Piper Sandler
Masimo shares likely to take 'another leg lower,' says Piper Sandler
03/17/22 Piper Sandler
Masimo price target lowered to $160 from $200 at Piper Sandler
02/18/22 Needham
Needham upgraded Masimo to Buy, sees selloff on Sound United deal as overdone
VRRM Verra Mobility
$16.57 /

+0.89 (+5.68%)

03/29/22 Deutsche Bank
Verra Mobility initiated with a Hold at Deutsche Bank
12/09/21 William Blair
Verra Mobility selloff on secondary a buying opportunity, says William Blair
05/26/21 Morgan Stanley
Verra Mobility downgraded to Equal Weight on valuation at Morgan Stanley
05/26/21 Morgan Stanley
Verra Mobility downgraded to Equal Weight from Overweight at Morgan Stanley
NNOX Nano-X Imaging
$10.98 /

+1.55 (+16.44%)

04/19/21 Ladenburg
Ladenburg starts Nano-X Imaging at Buy with $52 price target
04/19/21 Ladenburg
Nano-X Imaging initiated with a Buy at Ladenburg
DARE Dare Bioscience
$1.55 /

+0.09 (+6.16%)

03/31/22 Roth Capital
Dare Bioscience women's health pipeline remains valuable, says Roth Capital
01/19/22 Brookline
Dare Bioscience assumed with a Buy at Brookline
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
BOLT Bolt Biotherapeutics
$2.72 /

-0.06 (-2.16%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

VRRM Verra Mobility
$16.57 /

+0.89 (+5.68%)

VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

TSLA Tesla
$1,097.57 /

+3.66 (+0.33%)

TPX Tempur Sealy
$28.05 /

-0.95 (-3.28%)

SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

SHCR Sharecare
$2.73 /

-0.55 (-16.79%)

QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

PATH UiPath
$21.66 /

-7.38 (-25.41%)

NNOX Nano-X Imaging
$10.98 /

+1.55 (+16.44%)

NNDM Nano Dimension
$3.57 /

-0.26 (-6.80%)

MASI Masimo
$148.79 /

-6.28 (-4.05%)

JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

IQ iQIYI
$4.64 /

-0.405 (-8.03%)

HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

FLEX Flex
$18.96 /

+1.595 (+9.19%)

FIVE Five Below
$162.17 /

+1.65 (+1.03%)

FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

F Ford
$17.13 /

-0.15 (-0.87%)

EXFY Expensify
$16.27 /

-2.365 (-12.69%)

DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

DARE Dare Bioscience
$1.55 /

+0.09 (+6.16%)

COIN Coinbase
$193.50 /

-3.2 (-1.63%)

BOLT Bolt Biotherapeutics
$2.72 /

-0.06 (-2.16%)

BIDU Baidu
$134.85 /

-9.02 (-6.27%)

AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

AMD AMD
$111.17 /

-8.03 (-6.74%)

AAPL Apple
$177.06 /

-0.615 (-0.35%)

  • 07
    Jan
  • 08
    Dec
  • 10
    Nov
  • 19
    Aug
  • 29
    Jun
  • 18
    Jun
  • 14
    Apr
  • 14
    Apr
  • 21
    Apr
  • 06
    Apr
WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

TSLA Tesla
$1,097.57 /

+3.66 (+0.33%)

SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

NNOX Nano-X Imaging
$10.98 /

+1.55 (+16.44%)

JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

F Ford
$17.13 /

-0.15 (-0.87%)

DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

COIN Coinbase
$193.50 /

-3.2 (-1.63%)

BIDU Baidu
$134.85 /

-9.02 (-6.27%)

AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

AMLX Amylyx
$13.40 /

-1.55 (-10.37%)

AMD AMD
$111.17 /

-8.03 (-6.74%)

AAPL Apple
$177.06 /

-0.615 (-0.35%)

WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

VRRM Verra Mobility
$16.57 /

+0.89 (+5.68%)

VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

TPX Tempur Sealy
$28.05 /

-0.95 (-3.28%)

SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

PATH UiPath
$21.66 /

-7.38 (-25.41%)

NNDM Nano Dimension
$3.57 /

-0.26 (-6.80%)

MASI Masimo
$148.79 /

-6.28 (-4.05%)

JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

IQ iQIYI
$4.64 /

-0.405 (-8.03%)

HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

FLEX Flex
$18.96 /

+1.595 (+9.19%)

FIVE Five Below
$162.17 /

+1.65 (+1.03%)

FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

F Ford
$17.13 /

-0.15 (-0.87%)

EXFY Expensify
$16.27 /

-2.365 (-12.69%)

DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

DARE Dare Bioscience
$1.55 /

+0.09 (+6.16%)

COIN Coinbase
$193.50 /

-3.2 (-1.63%)

BOLT Bolt Biotherapeutics
$2.72 /

-0.06 (-2.16%)

AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

AMLX Amylyx
$13.40 /

-1.55 (-10.37%)

AMD AMD
$111.17 /

-8.03 (-6.74%)

WBA Walgreens Boots Alliance
$45.10 /

-2.34 (-4.93%)

VIPS Vipshop
$9.26 /

+0.05 (+0.54%)

TSLA Tesla
$1,097.57 /

+3.66 (+0.33%)

TPX Tempur Sealy
$28.05 /

-0.95 (-3.28%)

SNOW Snowflake
$235.25 /

+3.6 (+1.55%)

QCOM Qualcomm
$154.02 /

+1.295 (+0.85%)

PATH UiPath
$21.66 /

-7.38 (-25.41%)

NNOX Nano-X Imaging
$10.98 /

+1.55 (+16.44%)

NNDM Nano Dimension
$3.57 /

-0.26 (-6.80%)

JPM JPMorgan
$138.58 /

-1.91 (-1.36%)

IQ iQIYI
$4.64 /

-0.405 (-8.03%)

HPQ HP Inc.
$36.74 /

-2.095 (-5.39%)

FLEX Flex
$18.96 /

+1.595 (+9.19%)

FIVE Five Below
$162.17 /

+1.65 (+1.03%)

FB Meta Platforms
$224.95 /

-2.82 (-1.24%)

F Ford
$17.13 /

-0.15 (-0.87%)

EXFY Expensify
$16.27 /

-2.365 (-12.69%)

DELL Dell Technologies
$51.42 /

-2.86 (-5.27%)

COIN Coinbase
$193.50 /

-3.2 (-1.63%)

BIDU Baidu
$134.85 /

-9.02 (-6.27%)

AMZN Amazon.com
$3,304.86 /

-18.19 (-0.55%)

AMLX Amylyx
$13.40 /

-1.55 (-10.37%)

AMD AMD
$111.17 /

-8.03 (-6.74%)

AAPL Apple
$177.06 /

-0.615 (-0.35%)

Syndicate
Bolt Biotherapeutics files $250M mixed securities shelf  06:30
03/31/22
03/31
06:30
03/31/22
06:30
BOLT

Bolt Biotherapeutics

$2.79 /

-0.08 (-2.79%)

 
ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

Earnings
Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) » 16:16
03/30/22
03/30
16:16
03/30/22
16:16
BOLT

Bolt Biotherapeutics

$2.79 /

-0.08 (-2.79%)

Reports Q4 revenue…

Reports Q4 revenue $508,000, consensus $370,000. Cash, cash equivalents, and marketable securities were $271.6M as of December 31, 2021, compared to $22.8M as of December 31, 2020. Bolt Biotherapeutics expects its cash balance to fund operations into 2024. "In 2021, we demonstrated for the first time that our HER2-targeting Boltbody ISAC can increase myeloid cell infiltration and repolarize macrophages in the tumor microenvironment, and thereby, established proof of mechanism for our pioneering Boltbody ISAC platform. In our Phase 1/2 study, BDC-1001 was well tolerated at all dose levels tested with no dose-limiting toxicities. At the lower dose levels evaluated to date, we have seen stable disease in multiple different tumor types and a partial response that has now persisted for more than 60 weeks," said Randall Schatzman, CEO of Bolt Biotherapeutics. "We continue to explore dose levels expected to achieve our targeted higher drug exposures, and look forward to determining the recommended Phase 2 dose for BDC-1001 as monotherapy and in combination with Opdivo."

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

BOLT Bolt Biotherapeutics
$2.79 /

-0.08 (-2.79%)

Hot Stocks
Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer » 07:09
03/14/22
03/14
07:09
03/14/22
07:09
ELEV

Elevation Oncology

$2.99 /

+0.01 (+0.34%)

, BOLT

Bolt Biotherapeutics

$2.84 /

-0.235 (-7.64%)

Elevation Oncology (ELEV)…

Elevation Oncology (ELEV) announced the appointment of David Dornan, Ph.D. as the company's Chief Scientific Officer. Dr. Dornan joins Elevation Oncology from Bolt Biotherapeutics (BOLT).

ShowHide Related Items >><<
ELEV Elevation Oncology
$2.99 /

+0.01 (+0.34%)

BOLT Bolt Biotherapeutics
$2.84 /

-0.235 (-7.64%)

ELEV Elevation Oncology
$2.99 /

+0.01 (+0.34%)

03/04/22 Wedbush
Elevation Oncology price target lowered to $21 from $27 at Wedbush
12/23/21
Fly Intel: Top five analyst initiations
12/23/21 H.C. Wainwright
Elevation Oncology initiated with a Buy at H.C. Wainwright
07/20/21
Fly Intel: Top five analyst initiations
BOLT Bolt Biotherapeutics
$2.84 /

-0.235 (-7.64%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
ELEV Elevation Oncology
$2.99 /

+0.01 (+0.34%)

BOLT Bolt Biotherapeutics
$2.84 /

-0.235 (-7.64%)

  • 25
    Jun
BOLT Bolt Biotherapeutics
$2.84 /

-0.235 (-7.64%)

Over a quarter ago
Conference/Events
Guggenheim to hold a virtual conference » 04:55
02/11/22
02/11
04:55
02/11/22
04:55
ACET

Adicet Bio

$15.58 /

+0.525 (+3.49%)

, ADCT

ADC Therapeutics

$16.22 /

-1.1 (-6.35%)

, ALLO

Allogene Therapeutics

$10.63 /

-0.415 (-3.76%)

, BOLT

Bolt Biotherapeutics

$3.18 /

-0.21 (-6.19%)

, DCPH

Deciphera

$9.26 /

-0.145 (-1.54%)

, TNGX

Tango Therapeutics

$9.29 /

+0.02 (+0.22%)

, RLAY

Relay Therapeutics

$20.84 /

-1.355 (-6.11%)

, IMRX

Immuneering

$9.75 /

-0.65 (-6.25%)

, PMVP

PMV Pharmaceuticals

$16.26 /

-0.13 (-0.79%)

, FATE

Fate Therapeutics

$38.09 /

-2.8 (-6.85%)

, LLY

Eli Lilly

$239.61 /

-3.625 (-1.49%)

, ZYME

Zymeworks

$7.65 /

-0.43 (-5.33%)

, TARA

Protara Therapeutics

$5.38 /

+0.25 (+4.87%)

, ONTX

Onconova

$1.71 /

-0.07 (-3.93%)

, XLO

Xilio Therapeutics

$13.14 /

+2.28 (+20.99%)

, MGNX

MacroGenics

$11.49 /

-0.27 (-2.30%)

, KYMR

Kymera Therapeutics

$42.68 /

-0.34 (-0.79%)

, SWTX

SpringsWorks Therapeutics

$57.58 /

-0.62 (-1.07%)

, VBLT

VBL Therapeutics

$1.48 /

+0.1 (+7.25%)

, MRUS

Merus

$26.29 /

+0.25 (+0.96%)

, SRRA

Sierra Oncology

$31.95 /

-2.35 (-6.85%)

, IGMS

IGM Biosciences

$17.75 /

-1.105 (-5.86%)

, RPTX

Repare Therapeutics

$15.08 /

-0.47 (-3.02%)

, ERAS

Erasca

$11.98 /

-0.39 (-3.15%)

, BLUE

Bluebird Bio

$6.93 /

-0.42 (-5.71%)

, RVMD

Revolution Medicines

$21.16 /

-1.37 (-6.08%)

, RAIN

Rain Therapeutics

$7.49 /

-0.13 (-1.71%)

Virtual Oncology…

Virtual Oncology Conference to be held on February 9-11.

ShowHide Related Items >><<
ZYME Zymeworks
$7.65 /

-0.43 (-5.33%)

XLO Xilio Therapeutics
$13.14 /

+2.28 (+20.99%)

VBLT VBL Therapeutics
$1.48 /

+0.1 (+7.25%)

TNGX Tango Therapeutics
$9.29 /

+0.02 (+0.22%)

TARA Protara Therapeutics
$5.38 /

+0.25 (+4.87%)

SWTX SpringsWorks Therapeutics
$57.58 /

-0.62 (-1.07%)

SRRA Sierra Oncology
$31.95 /

-2.35 (-6.85%)

RPTX Repare Therapeutics
$15.08 /

-0.47 (-3.02%)

RLAY Relay Therapeutics
$20.84 /

-1.355 (-6.11%)

RAIN Rain Therapeutics
$7.49 /

-0.13 (-1.71%)

PMVP PMV Pharmaceuticals
$16.26 /

-0.13 (-0.79%)

ONTX Onconova
$1.71 /

-0.07 (-3.93%)

MRUS Merus
$26.29 /

+0.25 (+0.96%)

MGNX MacroGenics
$11.49 /

-0.27 (-2.30%)

LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

KYMR Kymera Therapeutics
$42.68 /

-0.34 (-0.79%)

IMRX Immuneering
$9.75 /

-0.65 (-6.25%)

IGMS IGM Biosciences
$17.75 /

-1.105 (-5.86%)

FATE Fate Therapeutics
$38.09 /

-2.8 (-6.85%)

ERAS Erasca
$11.98 /

-0.39 (-3.15%)

DCPH Deciphera
$9.26 /

-0.145 (-1.54%)

BOLT Bolt Biotherapeutics
$3.18 /

-0.21 (-6.19%)

BLUE Bluebird Bio
$6.93 /

-0.42 (-5.71%)

ALLO Allogene Therapeutics
$10.63 /

-0.415 (-3.76%)

ADCT ADC Therapeutics
$16.22 /

-1.1 (-6.35%)

ACET Adicet Bio
$15.58 /

+0.525 (+3.49%)

ACET Adicet Bio
$15.58 /

+0.525 (+3.49%)

01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/06/21 BTIG
Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG
12/06/21 Canaccord
Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data
12/06/21 Guggenheim
Adicet Bio price target raised to $33 from $22 at Guggenheim
ADCT ADC Therapeutics
$16.22 /

-1.1 (-6.35%)

02/01/22 Morgan Stanley
ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley
11/08/21 Wolfe Research
ADC Therapeutics initiated with an Outperform at Wolfe Research
09/07/21 Cantor Fitzgerald
ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald
08/09/21 RBC Capital
ADC Therapeutics initiated with an Outperform at RBC Capital
ALLO Allogene Therapeutics
$10.63 /

-0.415 (-3.76%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BOLT Bolt Biotherapeutics
$3.18 /

-0.21 (-6.19%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
DCPH Deciphera
$9.26 /

-0.145 (-1.54%)

02/08/22 Piper Sandler
Deciphera's Q4 update was in-line, says Piper Sandler
12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
TNGX Tango Therapeutics
$9.29 /

+0.02 (+0.22%)

09/20/21 SVB Leerink
SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform
09/20/21 SVB Leerink
Tango Therapeutics initiated with an Outperform at SVB Leerink
09/07/21
Fly Intel: Top five analyst initiations
09/07/21 Wedbush
Tango Therapeutics initiated with an Outperform at Wedbush
RLAY Relay Therapeutics
$20.84 /

-1.355 (-6.11%)

02/01/22 Berenberg
Relay Therapeutics initiated with a Buy at Berenberg
01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
IMRX Immuneering
$9.75 /

-0.65 (-6.25%)

01/07/22 Piper Sandler
Immuneering initiated with an Overweight at Piper Sandler
01/03/22 Guggenheim
Immuneering price target lowered to $30 from $42 at Guggenheim
08/24/21 Morgan Stanley
Immuneering initiated with an Equal Weight at Morgan Stanley
08/24/21 Jefferies
Immuneering initiated with a Buy at Jefferies
PMVP PMV Pharmaceuticals
$16.26 /

-0.13 (-0.79%)

09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
08/02/21 Guggenheim
PMV Pharmaceuticals initiated with a Buy at Guggenheim
07/29/21 H.C. Wainwright
PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright
FATE Fate Therapeutics
$38.09 /

-2.8 (-6.85%)

02/10/22 BMO Capital
Fate Therapeutics assumed with a Market Perform at BMO Capital
01/03/22 Guggenheim
Fate Therapeutics price target lowered to $78 from $107 at Guggenheim
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/15/21 Wedbush
Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74
LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

02/04/22 Morgan Stanley
Eli Lilly price target lowered to $265 from $272 at Morgan Stanley
02/04/22 Mizuho
Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho
02/03/22 Truist
Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist
01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
ZYME Zymeworks
$7.65 /

-0.43 (-5.33%)

02/09/22 Wells Fargo
Zymeworks price target lowered to $45 from $56 at Wells Fargo
12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
TARA Protara Therapeutics
$5.38 /

+0.25 (+4.87%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
ONTX Onconova
$1.71 /

-0.07 (-3.93%)

09/28/21 Guggenheim
Onconova price target lowered to $12 from $29 at Guggenheim
05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
XLO Xilio Therapeutics
$13.14 /

+2.28 (+20.99%)

01/10/22 H.C. Wainwright
Xilio Therapeutics initiated with a Buy at H.C. Wainwright
11/16/21 Morgan Stanley
Xilio Therapeutics initiated with an Overweight at Morgan Stanley
11/16/21 Raymond James
Xilio Therapeutics initiated with an Outperform at Raymond James
11/16/21 Guggenheim
Xilio Therapeutics initiated with a Buy at Guggenheim
MGNX MacroGenics
$11.49 /

-0.27 (-2.30%)

02/10/22 BMO Capital
MacroGenics initiated with an Outperform at BMO Capital
02/03/22 SMBC Nikko
MacroGenics initiated with an Outperform at SMBC Nikko
11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
KYMR Kymera Therapeutics
$42.68 /

-0.34 (-0.79%)

02/10/22 Wells Fargo
Wells Fargo bullish on Kymera Therapeutics, initiates with an Overweight
02/09/22 Wells Fargo
Kymera Therapeutics initiated with an Overweight at Wells Fargo
01/03/22 Piper Sandler
Piper names Kymera Therapeutics a top pick for 2022, ups target
SWTX SpringsWorks Therapeutics
$57.58 /

-0.62 (-1.07%)

10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
07/21/21 H.C. Wainwright
SpringsWorks price target raised to $136 from $124 at H.C. Wainwright
07/20/21 Goldman Sachs
SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs
VBLT VBL Therapeutics
$1.48 /

+0.1 (+7.25%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
MRUS Merus
$26.29 /

+0.25 (+0.96%)

02/10/22 BMO Capital
Merus initiated with an Outperform at BMO Capital
02/10/22 Needham
Merus initiated with a Buy at Needham
11/17/21
Fly Intel: Top five analyst initiations
SRRA Sierra Oncology
$31.95 /

-2.35 (-6.85%)

01/31/22 H.C. Wainwright
Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright
01/27/22 Oppenheimer
Sierra Oncology price target raised to $38 from $32 at Oppenheimer
11/30/21 Cantor Fitzgerald
Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald
11/05/21 H.C. Wainwright
Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright
IGMS IGM Biosciences
$17.75 /

-1.105 (-5.86%)

01/03/22 Guggenheim
IGM Biosciences price target lowered to $55 from $100 at Guggenheim
12/16/21 H.C. Wainwright
IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright
12/14/21 Baird
IGM Biosciences price target lowered to $65 from $90 at Baird
12/13/21 Morgan Stanley
Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns
RPTX Repare Therapeutics
$15.08 /

-0.47 (-3.02%)

11/18/21 Northland
Repare Therapeutics price target raised to $45 from $40 at Northland
11/10/21 Stifel
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report
09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
ERAS Erasca
$11.98 /

-0.39 (-3.15%)

01/03/22 Guggenheim
Erasca price target lowered to $20 from $25 at Guggenheim
08/10/21
Fly Intel: Top five analyst initiations
08/10/21 Evercore ISI
Erasca initiated with an Outperform at Evercore ISI
08/10/21 JPMorgan
Erasca initiated with an Overweight at JPMorgan
BLUE Bluebird Bio
$6.93 /

-0.42 (-5.71%)

01/05/22 Wells Fargo
Avrobio price target lowered to $8 from $36 at Wells Fargo
12/06/21 Cowen
Cowen starts Crispr at Market Perform as applications 'need maturing'
11/12/21 BMO Capital
Bluebird Bio price target lowered to $13 from $21 at BMO Capital
11/08/21 Canaccord
2seventy Bio initiated with a Buy at Canaccord
RVMD Revolution Medicines
$21.16 /

-1.37 (-6.08%)

11/12/21 H.C. Wainwright
Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright
09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
RAIN Rain Therapeutics
$7.49 /

-0.13 (-1.71%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
ZYME Zymeworks
$7.65 /

-0.43 (-5.33%)

XLO Xilio Therapeutics
$13.14 /

+2.28 (+20.99%)

VBLT VBL Therapeutics
$1.48 /

+0.1 (+7.25%)

TNGX Tango Therapeutics
$9.29 /

+0.02 (+0.22%)

TARA Protara Therapeutics
$5.38 /

+0.25 (+4.87%)

SWTX SpringsWorks Therapeutics
$57.58 /

-0.62 (-1.07%)

SRRA Sierra Oncology
$31.95 /

-2.35 (-6.85%)

RVMD Revolution Medicines
$21.16 /

-1.37 (-6.08%)

RPTX Repare Therapeutics
$15.08 /

-0.47 (-3.02%)

RLAY Relay Therapeutics
$20.84 /

-1.355 (-6.11%)

RAIN Rain Therapeutics
$7.49 /

-0.13 (-1.71%)

PMVP PMV Pharmaceuticals
$16.26 /

-0.13 (-0.79%)

MRUS Merus
$26.29 /

+0.25 (+0.96%)

MGNX MacroGenics
$11.49 /

-0.27 (-2.30%)

LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

KYMR Kymera Therapeutics
$42.68 /

-0.34 (-0.79%)

IMRX Immuneering
$9.75 /

-0.65 (-6.25%)

IGMS IGM Biosciences
$17.75 /

-1.105 (-5.86%)

FATE Fate Therapeutics
$38.09 /

-2.8 (-6.85%)

ERAS Erasca
$11.98 /

-0.39 (-3.15%)

DCPH Deciphera
$9.26 /

-0.145 (-1.54%)

BOLT Bolt Biotherapeutics
$3.18 /

-0.21 (-6.19%)

BLUE Bluebird Bio
$6.93 /

-0.42 (-5.71%)

ALLO Allogene Therapeutics
$10.63 /

-0.415 (-3.76%)

ADCT ADC Therapeutics
$16.22 /

-1.1 (-6.35%)

ACET Adicet Bio
$15.58 /

+0.525 (+3.49%)

  • 27
    Jan
  • 27
    Jan
  • 08
    Dec
  • 05
    Nov
  • 28
    Oct
  • 22
    Oct
  • 13
    Oct
  • 24
    Sep
  • 30
    Jul
  • 16
    Jul
  • 01
    Jul
  • 23
    Apr
  • 09
    Apr
  • 02
    Mar
ZYME Zymeworks
$7.65 /

-0.43 (-5.33%)

LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

ZYME Zymeworks
$7.65 /

-0.43 (-5.33%)

XLO Xilio Therapeutics
$13.14 /

+2.28 (+20.99%)

TARA Protara Therapeutics
$5.38 /

+0.25 (+4.87%)

SRRA Sierra Oncology
$31.95 /

-2.35 (-6.85%)

RLAY Relay Therapeutics
$20.84 /

-1.355 (-6.11%)

ONTX Onconova
$1.71 /

-0.07 (-3.93%)

MRUS Merus
$26.29 /

+0.25 (+0.96%)

MGNX MacroGenics
$11.49 /

-0.27 (-2.30%)

LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

IMRX Immuneering
$9.75 /

-0.65 (-6.25%)

IGMS IGM Biosciences
$17.75 /

-1.105 (-5.86%)

FATE Fate Therapeutics
$38.09 /

-2.8 (-6.85%)

DCPH Deciphera
$9.26 /

-0.145 (-1.54%)

BOLT Bolt Biotherapeutics
$3.18 /

-0.21 (-6.19%)

BLUE Bluebird Bio
$6.93 /

-0.42 (-5.71%)

ALLO Allogene Therapeutics
$10.63 /

-0.415 (-3.76%)

ACET Adicet Bio
$15.58 /

+0.525 (+3.49%)

SRRA Sierra Oncology
$31.95 /

-2.35 (-6.85%)

LLY Eli Lilly
$239.61 /

-3.625 (-1.49%)

BLUE Bluebird Bio
$6.93 /

-0.42 (-5.71%)

ALLO Allogene Therapeutics
$10.63 /

-0.415 (-3.76%)

Conference/Events
Guggenheim to hold a virtual conference » 04:55
02/10/22
02/10
04:55
02/10/22
04:55
ACET

Adicet Bio

$15.05 /

+1.39 (+10.18%)

, ADCT

ADC Therapeutics

$17.37 /

+1.07 (+6.56%)

, ALLO

Allogene Therapeutics

$11.05 /

+0.245 (+2.27%)

, BOLT

Bolt Biotherapeutics

$3.39 /

+0.08 (+2.42%)

, DCPH

Deciphera

$9.43 /

+1.29 (+15.85%)

, TNGX

Tango Therapeutics

$9.20 /

+0.205 (+2.28%)

, RLAY

Relay Therapeutics

$22.19 /

+1.33 (+6.38%)

, IMRX

Immuneering

$10.40 /

+0.38 (+3.79%)

, PMVP

PMV Pharmaceuticals

$16.44 /

+1.24 (+8.16%)

, FATE

Fate Therapeutics

$40.93 /

+1.29 (+3.25%)

, LLY

Eli Lilly

$243.24 /

+3.355 (+1.40%)

, ZYME

Zymeworks

$8.07 /

+0.45 (+5.91%)

, TARA

Protara Therapeutics

$5.13 /

+0.12 (+2.40%)

, ONTX

Onconova

$1.78 /

-0.01 (-0.56%)

, XLO

Xilio Therapeutics

$10.87 /

+0.54 (+5.23%)

, MGNX

MacroGenics

$11.76 /

+0.25 (+2.17%)

, KYMR

Kymera Therapeutics

$43.02 /

+1.46 (+3.51%)

, SWTX

SpringsWorks Therapeutics

$58.20 /

+5.09 (+9.58%)

, VBLT

VBL Therapeutics

$1.38 /

+0.09 (+6.98%)

, MRUS

Merus

$26.02 /

+0.78 (+3.09%)

, SRRA

Sierra Oncology

$34.21 /

+1.98 (+6.14%)

, IGMS

IGM Biosciences

$18.86 /

+1.625 (+9.43%)

, RPTX

Repare Therapeutics

$15.55 /

+0.6 (+4.01%)

, ERAS

Erasca

$12.39 /

+0.52 (+4.38%)

, BLUE

Bluebird Bio

$7.35 /

+0.32 (+4.55%)

, RVMD

Revolution Medicines

$22.57 /

+1.17 (+5.47%)

, RAIN

Rain Therapeutics

$7.62 /

+0.41 (+5.69%)

Virtual Oncology…

Virtual Oncology Conference to be held on February 9-11.

ShowHide Related Items >><<
ZYME Zymeworks
$8.07 /

+0.45 (+5.91%)

XLO Xilio Therapeutics
$10.87 /

+0.54 (+5.23%)

VBLT VBL Therapeutics
$1.38 /

+0.09 (+6.98%)

TNGX Tango Therapeutics
$9.20 /

+0.205 (+2.28%)

TARA Protara Therapeutics
$5.13 /

+0.12 (+2.40%)

SWTX SpringsWorks Therapeutics
$58.20 /

+5.09 (+9.58%)

SRRA Sierra Oncology
$34.21 /

+1.98 (+6.14%)

RPTX Repare Therapeutics
$15.55 /

+0.6 (+4.01%)

RLAY Relay Therapeutics
$22.19 /

+1.33 (+6.38%)

RAIN Rain Therapeutics
$7.62 /

+0.41 (+5.69%)

PMVP PMV Pharmaceuticals
$16.44 /

+1.24 (+8.16%)

ONTX Onconova
$1.78 /

-0.01 (-0.56%)

MRUS Merus
$26.02 /

+0.78 (+3.09%)

MGNX MacroGenics
$11.76 /

+0.25 (+2.17%)

LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

KYMR Kymera Therapeutics
$43.02 /

+1.46 (+3.51%)

IMRX Immuneering
$10.40 /

+0.38 (+3.79%)

IGMS IGM Biosciences
$18.86 /

+1.625 (+9.43%)

FATE Fate Therapeutics
$40.93 /

+1.29 (+3.25%)

ERAS Erasca
$12.39 /

+0.52 (+4.38%)

DCPH Deciphera
$9.43 /

+1.29 (+15.85%)

BOLT Bolt Biotherapeutics
$3.39 /

+0.08 (+2.42%)

BLUE Bluebird Bio
$7.35 /

+0.32 (+4.55%)

ALLO Allogene Therapeutics
$11.05 /

+0.245 (+2.27%)

ADCT ADC Therapeutics
$17.37 /

+1.07 (+6.56%)

ACET Adicet Bio
$15.05 /

+1.39 (+10.18%)

ACET Adicet Bio
$15.05 /

+1.39 (+10.18%)

01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/06/21 BTIG
Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG
12/06/21 Canaccord
Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data
12/06/21 Guggenheim
Adicet Bio price target raised to $33 from $22 at Guggenheim
ADCT ADC Therapeutics
$17.37 /

+1.07 (+6.56%)

02/01/22 Morgan Stanley
ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley
11/08/21 Wolfe Research
ADC Therapeutics initiated with an Outperform at Wolfe Research
09/07/21 Cantor Fitzgerald
ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald
08/09/21 RBC Capital
ADC Therapeutics initiated with an Outperform at RBC Capital
ALLO Allogene Therapeutics
$11.05 /

+0.245 (+2.27%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BOLT Bolt Biotherapeutics
$3.39 /

+0.08 (+2.42%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
DCPH Deciphera
$9.43 /

+1.29 (+15.85%)

02/08/22 Piper Sandler
Deciphera's Q4 update was in-line, says Piper Sandler
12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
TNGX Tango Therapeutics
$9.20 /

+0.205 (+2.28%)

09/20/21 SVB Leerink
SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform
09/20/21 SVB Leerink
Tango Therapeutics initiated with an Outperform at SVB Leerink
09/07/21
Fly Intel: Top five analyst initiations
09/07/21 Wedbush
Tango Therapeutics initiated with an Outperform at Wedbush
RLAY Relay Therapeutics
$22.19 /

+1.33 (+6.38%)

02/01/22 Berenberg
Relay Therapeutics initiated with a Buy at Berenberg
01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
IMRX Immuneering
$10.40 /

+0.38 (+3.79%)

01/07/22 Piper Sandler
Immuneering initiated with an Overweight at Piper Sandler
01/03/22 Guggenheim
Immuneering price target lowered to $30 from $42 at Guggenheim
08/24/21 Morgan Stanley
Immuneering initiated with an Equal Weight at Morgan Stanley
08/24/21 Jefferies
Immuneering initiated with a Buy at Jefferies
PMVP PMV Pharmaceuticals
$16.44 /

+1.24 (+8.16%)

09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
08/02/21 Guggenheim
PMV Pharmaceuticals initiated with a Buy at Guggenheim
07/29/21 H.C. Wainwright
PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright
FATE Fate Therapeutics
$40.93 /

+1.29 (+3.25%)

01/03/22 Guggenheim
Fate Therapeutics price target lowered to $78 from $107 at Guggenheim
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/15/21 Wedbush
Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74
12/15/21 Wedbush
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

02/04/22 Morgan Stanley
Eli Lilly price target lowered to $265 from $272 at Morgan Stanley
02/04/22 Mizuho
Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho
02/03/22 Truist
Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist
01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
ZYME Zymeworks
$8.07 /

+0.45 (+5.91%)

02/09/22 Wells Fargo
Zymeworks price target lowered to $45 from $56 at Wells Fargo
12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
TARA Protara Therapeutics
$5.13 /

+0.12 (+2.40%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
ONTX Onconova
$1.78 /

-0.01 (-0.56%)

09/28/21 Guggenheim
Onconova price target lowered to $12 from $29 at Guggenheim
05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
XLO Xilio Therapeutics
$10.87 /

+0.54 (+5.23%)

01/10/22 H.C. Wainwright
Xilio Therapeutics initiated with a Buy at H.C. Wainwright
11/16/21 Morgan Stanley
Xilio Therapeutics initiated with an Overweight at Morgan Stanley
11/16/21 Raymond James
Xilio Therapeutics initiated with an Outperform at Raymond James
11/16/21 Guggenheim
Xilio Therapeutics initiated with a Buy at Guggenheim
MGNX MacroGenics
$11.76 /

+0.25 (+2.17%)

02/03/22 SMBC Nikko
MacroGenics initiated with an Outperform at SMBC Nikko
11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
KYMR Kymera Therapeutics
$43.02 /

+1.46 (+3.51%)

02/09/22 Wells Fargo
Kymera Therapeutics initiated with an Overweight at Wells Fargo
01/03/22 Piper Sandler
Piper names Kymera Therapeutics a top pick for 2022, ups target
10/13/21 Brookline
Kymera Therapeutics initiated with Buy, $80 target at Brookline
SWTX SpringsWorks Therapeutics
$58.20 /

+5.09 (+9.58%)

10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
07/21/21 H.C. Wainwright
SpringsWorks price target raised to $136 from $124 at H.C. Wainwright
07/20/21 Goldman Sachs
SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs
VBLT VBL Therapeutics
$1.38 /

+0.09 (+6.98%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
MRUS Merus
$26.02 /

+0.78 (+3.09%)

11/17/21
Fly Intel: Top five analyst initiations
11/17/21 Guggenheim
Merus assumed with a Buy at Guggenheim
11/12/21 H.C. Wainwright
Merus price target raised to $45 from $30 at H.C. Wainwright
SRRA Sierra Oncology
$34.21 /

+1.98 (+6.14%)

01/31/22 H.C. Wainwright
Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright
01/27/22 Oppenheimer
Sierra Oncology price target raised to $38 from $32 at Oppenheimer
11/30/21 Cantor Fitzgerald
Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald
11/05/21 H.C. Wainwright
Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright
IGMS IGM Biosciences
$18.86 /

+1.625 (+9.43%)

01/03/22 Guggenheim
IGM Biosciences price target lowered to $55 from $100 at Guggenheim
12/16/21 H.C. Wainwright
IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright
12/14/21 Baird
IGM Biosciences price target lowered to $65 from $90 at Baird
12/13/21 Morgan Stanley
Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns
RPTX Repare Therapeutics
$15.55 /

+0.6 (+4.01%)

11/18/21 Northland
Repare Therapeutics price target raised to $45 from $40 at Northland
11/10/21 Stifel
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report
09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
ERAS Erasca
$12.39 /

+0.52 (+4.38%)

01/03/22 Guggenheim
Erasca price target lowered to $20 from $25 at Guggenheim
08/10/21
Fly Intel: Top five analyst initiations
08/10/21 Evercore ISI
Erasca initiated with an Outperform at Evercore ISI
08/10/21 JPMorgan
Erasca initiated with an Overweight at JPMorgan
BLUE Bluebird Bio
$7.35 /

+0.32 (+4.55%)

01/05/22 Wells Fargo
Avrobio price target lowered to $8 from $36 at Wells Fargo
12/06/21 Cowen
Cowen starts Crispr at Market Perform as applications 'need maturing'
11/12/21 BMO Capital
Bluebird Bio price target lowered to $13 from $21 at BMO Capital
11/08/21 Canaccord
2seventy Bio initiated with a Buy at Canaccord
RVMD Revolution Medicines
$22.57 /

+1.17 (+5.47%)

11/12/21 H.C. Wainwright
Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright
09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
RAIN Rain Therapeutics
$7.62 /

+0.41 (+5.69%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
ZYME Zymeworks
$8.07 /

+0.45 (+5.91%)

XLO Xilio Therapeutics
$10.87 /

+0.54 (+5.23%)

VBLT VBL Therapeutics
$1.38 /

+0.09 (+6.98%)

TNGX Tango Therapeutics
$9.20 /

+0.205 (+2.28%)

TARA Protara Therapeutics
$5.13 /

+0.12 (+2.40%)

SWTX SpringsWorks Therapeutics
$58.20 /

+5.09 (+9.58%)

SRRA Sierra Oncology
$34.21 /

+1.98 (+6.14%)

RVMD Revolution Medicines
$22.57 /

+1.17 (+5.47%)

RPTX Repare Therapeutics
$15.55 /

+0.6 (+4.01%)

RLAY Relay Therapeutics
$22.19 /

+1.33 (+6.38%)

RAIN Rain Therapeutics
$7.62 /

+0.41 (+5.69%)

PMVP PMV Pharmaceuticals
$16.44 /

+1.24 (+8.16%)

MRUS Merus
$26.02 /

+0.78 (+3.09%)

MGNX MacroGenics
$11.76 /

+0.25 (+2.17%)

LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

KYMR Kymera Therapeutics
$43.02 /

+1.46 (+3.51%)

IMRX Immuneering
$10.40 /

+0.38 (+3.79%)

IGMS IGM Biosciences
$18.86 /

+1.625 (+9.43%)

FATE Fate Therapeutics
$40.93 /

+1.29 (+3.25%)

ERAS Erasca
$12.39 /

+0.52 (+4.38%)

DCPH Deciphera
$9.43 /

+1.29 (+15.85%)

BOLT Bolt Biotherapeutics
$3.39 /

+0.08 (+2.42%)

BLUE Bluebird Bio
$7.35 /

+0.32 (+4.55%)

ALLO Allogene Therapeutics
$11.05 /

+0.245 (+2.27%)

ADCT ADC Therapeutics
$17.37 /

+1.07 (+6.56%)

ACET Adicet Bio
$15.05 /

+1.39 (+10.18%)

  • 27
    Jan
  • 27
    Jan
  • 08
    Dec
  • 05
    Nov
  • 28
    Oct
  • 22
    Oct
  • 13
    Oct
  • 24
    Sep
  • 30
    Jul
  • 16
    Jul
  • 01
    Jul
  • 23
    Apr
  • 09
    Apr
  • 02
    Mar
  • 11
    Feb
ZYME Zymeworks
$8.07 /

+0.45 (+5.91%)

LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

ZYME Zymeworks
$8.07 /

+0.45 (+5.91%)

XLO Xilio Therapeutics
$10.87 /

+0.54 (+5.23%)

TARA Protara Therapeutics
$5.13 /

+0.12 (+2.40%)

SRRA Sierra Oncology
$34.21 /

+1.98 (+6.14%)

RLAY Relay Therapeutics
$22.19 /

+1.33 (+6.38%)

ONTX Onconova
$1.78 /

-0.01 (-0.56%)

MRUS Merus
$26.02 /

+0.78 (+3.09%)

MGNX MacroGenics
$11.76 /

+0.25 (+2.17%)

LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

IMRX Immuneering
$10.40 /

+0.38 (+3.79%)

IGMS IGM Biosciences
$18.86 /

+1.625 (+9.43%)

FATE Fate Therapeutics
$40.93 /

+1.29 (+3.25%)

DCPH Deciphera
$9.43 /

+1.29 (+15.85%)

BOLT Bolt Biotherapeutics
$3.39 /

+0.08 (+2.42%)

BLUE Bluebird Bio
$7.35 /

+0.32 (+4.55%)

ALLO Allogene Therapeutics
$11.05 /

+0.245 (+2.27%)

ACET Adicet Bio
$15.05 /

+1.39 (+10.18%)

SRRA Sierra Oncology
$34.21 /

+1.98 (+6.14%)

LLY Eli Lilly
$243.24 /

+3.355 (+1.40%)

BLUE Bluebird Bio
$7.35 /

+0.32 (+4.55%)

ALLO Allogene Therapeutics
$11.05 /

+0.245 (+2.27%)

Conference/Events
Guggenheim to hold a virtual conference » 10:21
02/09/22
02/09
10:21
02/09/22
10:21
ACET

Adicet Bio

$14.21 /

+0.55 (+4.03%)

, ADCT

ADC Therapeutics

$16.70 /

+0.4 (+2.45%)

, ALLO

Allogene Therapeutics

$11.12 /

+0.32 (+2.96%)

, BOLT

Bolt Biotherapeutics

$3.35 /

+0.04 (+1.21%)

, DCPH

Deciphera

$8.89 /

+0.75 (+9.21%)

, TNGX

Tango Therapeutics

$9.00 /

+ (+0.00%)

, RLAY

Relay Therapeutics

$21.64 /

+0.78 (+3.74%)

, IMRX

Immuneering

$9.94 /

-0.08 (-0.80%)

, PMVP

PMV Pharmaceuticals

$15.61 /

+0.41 (+2.70%)

, FATE

Fate Therapeutics

$41.65 /

+2.01 (+5.07%)

, LLY

Eli Lilly

$244.29 /

+4.405 (+1.84%)

, ZYME

Zymeworks

$7.87 /

+0.25 (+3.28%)

, TARA

Protara Therapeutics

$5.04 /

+0.03 (+0.60%)

, ONTX

Onconova

$1.74 /

-0.05 (-2.79%)

, XLO

Xilio Therapeutics

$10.43 /

+0.1 (+0.97%)

, MGNX

MacroGenics

$11.89 /

+0.38 (+3.30%)

, KYMR

Kymera Therapeutics

$42.77 /

+1.21 (+2.91%)

, SWTX

SpringsWorks Therapeutics

$55.25 /

+2.14 (+4.03%)

, VBLT

VBL Therapeutics

$1.32 /

+0.03 (+2.33%)

, MRUS

Merus

$25.34 /

+0.1 (+0.40%)

, SRRA

Sierra Oncology

$32.70 /

+0.47 (+1.46%)

, IGMS

IGM Biosciences

$18.00 /

+0.77 (+4.47%)

, RPTX

Repare Therapeutics

$15.68 /

+0.73 (+4.88%)

, ERAS

Erasca

$12.23 /

+0.36 (+3.03%)

, BLUE

Bluebird Bio

$7.24 /

+0.21 (+2.99%)

, RVMD

Revolution Medicines

$22.38 /

+0.98 (+4.58%)

, RAIN

Rain Therapeutics

$7.70 /

+0.49 (+6.80%)

Virtual Oncology…

Virtual Oncology Conference to be held on February 9-11.

ShowHide Related Items >><<
ZYME Zymeworks
$7.87 /

+0.25 (+3.28%)

XLO Xilio Therapeutics
$10.43 /

+0.1 (+0.97%)

VBLT VBL Therapeutics
$1.32 /

+0.03 (+2.33%)

TNGX Tango Therapeutics
$9.00 /

+ (+0.00%)

TARA Protara Therapeutics
$5.04 /

+0.03 (+0.60%)

SWTX SpringsWorks Therapeutics
$55.25 /

+2.14 (+4.03%)

SRRA Sierra Oncology
$32.70 /

+0.47 (+1.46%)

RPTX Repare Therapeutics
$15.68 /

+0.73 (+4.88%)

RLAY Relay Therapeutics
$21.64 /

+0.78 (+3.74%)

RAIN Rain Therapeutics
$7.70 /

+0.49 (+6.80%)

PMVP PMV Pharmaceuticals
$15.61 /

+0.41 (+2.70%)

ONTX Onconova
$1.74 /

-0.05 (-2.79%)

MRUS Merus
$25.34 /

+0.1 (+0.40%)

MGNX MacroGenics
$11.89 /

+0.38 (+3.30%)

LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

KYMR Kymera Therapeutics
$42.77 /

+1.21 (+2.91%)

IMRX Immuneering
$9.94 /

-0.08 (-0.80%)

IGMS IGM Biosciences
$18.00 /

+0.77 (+4.47%)

FATE Fate Therapeutics
$41.65 /

+2.01 (+5.07%)

ERAS Erasca
$12.23 /

+0.36 (+3.03%)

DCPH Deciphera
$8.89 /

+0.75 (+9.21%)

BOLT Bolt Biotherapeutics
$3.35 /

+0.04 (+1.21%)

BLUE Bluebird Bio
$7.24 /

+0.21 (+2.99%)

ALLO Allogene Therapeutics
$11.12 /

+0.32 (+2.96%)

ADCT ADC Therapeutics
$16.70 /

+0.4 (+2.45%)

ACET Adicet Bio
$14.21 /

+0.55 (+4.03%)

ACET Adicet Bio
$14.21 /

+0.55 (+4.03%)

01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/06/21 BTIG
Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG
12/06/21 Canaccord
Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data
12/06/21 Guggenheim
Adicet Bio price target raised to $33 from $22 at Guggenheim
ADCT ADC Therapeutics
$16.70 /

+0.4 (+2.45%)

02/01/22 Morgan Stanley
ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley
11/08/21 Wolfe Research
ADC Therapeutics initiated with an Outperform at Wolfe Research
09/07/21 Cantor Fitzgerald
ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald
08/09/21 RBC Capital
ADC Therapeutics initiated with an Outperform at RBC Capital
ALLO Allogene Therapeutics
$11.12 /

+0.32 (+2.96%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BOLT Bolt Biotherapeutics
$3.35 /

+0.04 (+1.21%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
DCPH Deciphera
$8.89 /

+0.75 (+9.21%)

02/08/22 Piper Sandler
Deciphera's Q4 update was in-line, says Piper Sandler
12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
TNGX Tango Therapeutics
$9.00 /

+ (+0.00%)

09/20/21 SVB Leerink
SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform
09/20/21 SVB Leerink
Tango Therapeutics initiated with an Outperform at SVB Leerink
09/07/21
Fly Intel: Top five analyst initiations
09/07/21 Wedbush
Tango Therapeutics initiated with an Outperform at Wedbush
RLAY Relay Therapeutics
$21.64 /

+0.78 (+3.74%)

02/01/22 Berenberg
Relay Therapeutics initiated with a Buy at Berenberg
01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
IMRX Immuneering
$9.94 /

-0.08 (-0.80%)

01/07/22 Piper Sandler
Immuneering initiated with an Overweight at Piper Sandler
01/03/22 Guggenheim
Immuneering price target lowered to $30 from $42 at Guggenheim
08/24/21 Morgan Stanley
Immuneering initiated with an Equal Weight at Morgan Stanley
08/24/21 Jefferies
Immuneering initiated with a Buy at Jefferies
PMVP PMV Pharmaceuticals
$15.61 /

+0.41 (+2.70%)

09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
08/02/21 Guggenheim
PMV Pharmaceuticals initiated with a Buy at Guggenheim
07/29/21 H.C. Wainwright
PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright
FATE Fate Therapeutics
$41.65 /

+2.01 (+5.07%)

01/03/22 Guggenheim
Fate Therapeutics price target lowered to $78 from $107 at Guggenheim
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/15/21 Wedbush
Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74
12/15/21 Wedbush
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

02/04/22 Morgan Stanley
Eli Lilly price target lowered to $265 from $272 at Morgan Stanley
02/04/22 Mizuho
Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho
02/03/22 Truist
Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist
01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
ZYME Zymeworks
$7.87 /

+0.25 (+3.28%)

02/09/22 Wells Fargo
Zymeworks price target lowered to $45 from $56 at Wells Fargo
12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
TARA Protara Therapeutics
$5.04 /

+0.03 (+0.60%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
ONTX Onconova
$1.74 /

-0.05 (-2.79%)

09/28/21 Guggenheim
Onconova price target lowered to $12 from $29 at Guggenheim
05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
XLO Xilio Therapeutics
$10.43 /

+0.1 (+0.97%)

01/10/22 H.C. Wainwright
Xilio Therapeutics initiated with a Buy at H.C. Wainwright
11/16/21 Morgan Stanley
Xilio Therapeutics initiated with an Overweight at Morgan Stanley
11/16/21 Raymond James
Xilio Therapeutics initiated with an Outperform at Raymond James
11/16/21 Guggenheim
Xilio Therapeutics initiated with a Buy at Guggenheim
MGNX MacroGenics
$11.89 /

+0.38 (+3.30%)

02/03/22 SMBC Nikko
MacroGenics initiated with an Outperform at SMBC Nikko
11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
KYMR Kymera Therapeutics
$42.77 /

+1.21 (+2.91%)

01/03/22 Piper Sandler
Piper names Kymera Therapeutics a top pick for 2022, ups target
10/13/21 Brookline
Kymera Therapeutics initiated with Buy, $80 target at Brookline
10/12/21 Brookline
Kymera Therapeutics initiated with a Buy at Brookline
SWTX SpringsWorks Therapeutics
$55.25 /

+2.14 (+4.03%)

10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
07/21/21 H.C. Wainwright
SpringsWorks price target raised to $136 from $124 at H.C. Wainwright
07/20/21 Goldman Sachs
SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs
VBLT VBL Therapeutics
$1.32 /

+0.03 (+2.33%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
MRUS Merus
$25.34 /

+0.1 (+0.40%)

11/17/21
Fly Intel: Top five analyst initiations
11/17/21 Guggenheim
Merus assumed with a Buy at Guggenheim
11/12/21 H.C. Wainwright
Merus price target raised to $45 from $30 at H.C. Wainwright
SRRA Sierra Oncology
$32.70 /

+0.47 (+1.46%)

01/31/22 H.C. Wainwright
Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright
01/27/22 Oppenheimer
Sierra Oncology price target raised to $38 from $32 at Oppenheimer
11/30/21 Cantor Fitzgerald
Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald
11/05/21 H.C. Wainwright
Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright
IGMS IGM Biosciences
$18.00 /

+0.77 (+4.47%)

01/03/22 Guggenheim
IGM Biosciences price target lowered to $55 from $100 at Guggenheim
12/16/21 H.C. Wainwright
IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright
12/14/21 Baird
IGM Biosciences price target lowered to $65 from $90 at Baird
12/13/21 Morgan Stanley
Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns
RPTX Repare Therapeutics
$15.68 /

+0.73 (+4.88%)

11/18/21 Northland
Repare Therapeutics price target raised to $45 from $40 at Northland
11/10/21 Stifel
Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report
09/22/21 Stifel
Repare Therapeutics initiated with a Buy at Stifel
09/13/21 H.C. Wainwright
Repare Therapeutics initiated with a Buy at H.C. Wainwright
ERAS Erasca
$12.23 /

+0.36 (+3.03%)

01/03/22 Guggenheim
Erasca price target lowered to $20 from $25 at Guggenheim
08/10/21
Fly Intel: Top five analyst initiations
08/10/21 Evercore ISI
Erasca initiated with an Outperform at Evercore ISI
08/10/21 JPMorgan
Erasca initiated with an Overweight at JPMorgan
BLUE Bluebird Bio
$7.24 /

+0.21 (+2.99%)

01/05/22 Wells Fargo
Avrobio price target lowered to $8 from $36 at Wells Fargo
12/06/21 Cowen
Cowen starts Crispr at Market Perform as applications 'need maturing'
11/12/21 BMO Capital
Bluebird Bio price target lowered to $13 from $21 at BMO Capital
11/08/21 Canaccord
2seventy Bio initiated with a Buy at Canaccord
RVMD Revolution Medicines
$22.38 /

+0.98 (+4.58%)

11/12/21 H.C. Wainwright
Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright
09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
RAIN Rain Therapeutics
$7.70 /

+0.49 (+6.80%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
ZYME Zymeworks
$7.87 /

+0.25 (+3.28%)

XLO Xilio Therapeutics
$10.43 /

+0.1 (+0.97%)

VBLT VBL Therapeutics
$1.32 /

+0.03 (+2.33%)

TNGX Tango Therapeutics
$9.00 /

+ (+0.00%)

TARA Protara Therapeutics
$5.04 /

+0.03 (+0.60%)

SWTX SpringsWorks Therapeutics
$55.25 /

+2.14 (+4.03%)

SRRA Sierra Oncology
$32.70 /

+0.47 (+1.46%)

RVMD Revolution Medicines
$22.38 /

+0.98 (+4.58%)

RPTX Repare Therapeutics
$15.68 /

+0.73 (+4.88%)

RLAY Relay Therapeutics
$21.64 /

+0.78 (+3.74%)

RAIN Rain Therapeutics
$7.70 /

+0.49 (+6.80%)

PMVP PMV Pharmaceuticals
$15.61 /

+0.41 (+2.70%)

MRUS Merus
$25.34 /

+0.1 (+0.40%)

MGNX MacroGenics
$11.89 /

+0.38 (+3.30%)

LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

KYMR Kymera Therapeutics
$42.77 /

+1.21 (+2.91%)

IMRX Immuneering
$9.94 /

-0.08 (-0.80%)

IGMS IGM Biosciences
$18.00 /

+0.77 (+4.47%)

FATE Fate Therapeutics
$41.65 /

+2.01 (+5.07%)

ERAS Erasca
$12.23 /

+0.36 (+3.03%)

DCPH Deciphera
$8.89 /

+0.75 (+9.21%)

BOLT Bolt Biotherapeutics
$3.35 /

+0.04 (+1.21%)

BLUE Bluebird Bio
$7.24 /

+0.21 (+2.99%)

ALLO Allogene Therapeutics
$11.12 /

+0.32 (+2.96%)

ADCT ADC Therapeutics
$16.70 /

+0.4 (+2.45%)

ACET Adicet Bio
$14.21 /

+0.55 (+4.03%)

  • 27
    Jan
  • 27
    Jan
  • 08
    Dec
  • 05
    Nov
  • 28
    Oct
  • 22
    Oct
  • 13
    Oct
  • 24
    Sep
  • 30
    Jul
  • 16
    Jul
  • 01
    Jul
  • 23
    Apr
  • 09
    Apr
  • 02
    Mar
  • 11
    Feb
  • 10
    Feb
ZYME Zymeworks
$7.87 /

+0.25 (+3.28%)

LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

ZYME Zymeworks
$7.87 /

+0.25 (+3.28%)

XLO Xilio Therapeutics
$10.43 /

+0.1 (+0.97%)

TARA Protara Therapeutics
$5.04 /

+0.03 (+0.60%)

SRRA Sierra Oncology
$32.70 /

+0.47 (+1.46%)

RLAY Relay Therapeutics
$21.64 /

+0.78 (+3.74%)

ONTX Onconova
$1.74 /

-0.05 (-2.79%)

MRUS Merus
$25.34 /

+0.1 (+0.40%)

MGNX MacroGenics
$11.89 /

+0.38 (+3.30%)

LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

IMRX Immuneering
$9.94 /

-0.08 (-0.80%)

IGMS IGM Biosciences
$18.00 /

+0.77 (+4.47%)

FATE Fate Therapeutics
$41.65 /

+2.01 (+5.07%)

DCPH Deciphera
$8.89 /

+0.75 (+9.21%)

BOLT Bolt Biotherapeutics
$3.35 /

+0.04 (+1.21%)

BLUE Bluebird Bio
$7.24 /

+0.21 (+2.99%)

ALLO Allogene Therapeutics
$11.12 /

+0.32 (+2.96%)

ACET Adicet Bio
$14.21 /

+0.55 (+4.03%)

SRRA Sierra Oncology
$32.70 /

+0.47 (+1.46%)

LLY Eli Lilly
$244.29 /

+4.405 (+1.84%)

BLUE Bluebird Bio
$7.24 /

+0.21 (+2.99%)

ALLO Allogene Therapeutics
$11.12 /

+0.32 (+2.96%)

Hot Stocks
Bolt doses first patient with BDC-1001 in combination with OPDIVO » 08:14
01/06/22
01/06
08:14
01/06/22
08:14
BOLT

Bolt Biotherapeutics

$4.16 /

-0.39 (-8.57%)

, BMY

Bristol-Myers

$61.60 /

+0.01 (+0.02%)

Bolt Biotherapeutics…

Bolt Biotherapeutics (BOLT) announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb's (BMY) PD-1 checkpoint inhibitor OPDIVO. BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate in development for the treatment of patients with HER2-expressing solid tumors. "We are excited to evaluate BDC-1001 in combination with nivolumab, a leading PD-1 checkpoint inhibitor. Pairing BDC-1001's mechanism of action with the checkpoint inhibitor approach has the potential to yield a stronger, targeted modulation of the immune system. Initial safety and early efficacy findings reported from the ongoing monotherapy arm of the Phase 1/2 clinical trial make BDC-1001 a potentially promising candidate for the treatment of patients with HER2-expressing solid tumors," said Edith Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$4.16 /

-0.39 (-8.57%)

BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

BOLT Bolt Biotherapeutics
$4.16 /

-0.39 (-8.57%)

01/06/22 Morgan Stanley
Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
12/06/21 Stifel
Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
12/20/21 JPMorgan
Bristol-Myers shares should rebound into 2022, says JPMorgan
BOLT Bolt Biotherapeutics
$4.16 /

-0.39 (-8.57%)

BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

  • 05
    Feb
BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

BOLT Bolt Biotherapeutics
$4.16 /

-0.39 (-8.57%)

BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

BMY Bristol-Myers
$61.60 /

+0.01 (+0.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.